Autor: |
Peng Sun, Zhenfeng Li, Zaojun Yan, Zhaofeng Wang, Peng Zheng, Mingliang Wang, Xu Chang, Zihao Liu, Jianxin Zhang, Huiyong Wu, Wenbo Shao, Dewen Xue, Jinming Yu |
Jazyk: |
angličtina |
Rok vydání: |
2024 |
Předmět: |
|
Zdroj: |
BMC Cancer, Vol 24, Iss 1, Pp 1-14 (2024) |
Druh dokumentu: |
article |
ISSN: |
1471-2407 |
DOI: |
10.1186/s12885-024-12680-1 |
Popis: |
Abstract Lenvatinib, a multitarget kinase inhibitor, has been proven to be effective in the treatment of advanced hepatocellular carcinoma. It has been previously demonstrated that tumour associated macrophages (TAMs) in tumour tissues can promote HCC growth, invasion and metastasis. Furthermore, lenvatinib has certain immunomodulatory effects on the treatment of HCC. However, the role of lenvatinib in macrophage polarization during HCC treatment has not been fully explored. In this study, we used a variety of experimental methods both in vitro and in vivo to investigate the effect of lenvatinib on TAMs during HCC progression. This study is the first to show that lenvatinib can alter macrophage polarization in both humans and mice. Moreover, macrophages treated with lenvatinib in vitro displayed enhanced classically activated macrophages (M1) activity and suppressed liver cancer cell proliferation, invasion, and migration. Furthermore, during the progression of M1 macrophage polarization induced by lenvatinib, STAT-1 was the main target transcription factor, and inhibiting STAT-1 activity reversed the effect of lenvatinib. Overall, the present study provides a theoretical basis for the immunomodulatory function of lenvatinib in the treatment of HCC. |
Databáze: |
Directory of Open Access Journals |
Externí odkaz: |
|